Aissaoui Salima, Ouled-Haddar Houria, Sifour Mohamed, Beggah Chérifa, Benhamada Farida
Laboratory of Molecular Toxicology, Faculty of Nature and life Sciences, University of Mohammed Seddik Benyahia - Jijel, 98 Ouled Aissa-Jijel 1800-Algeria, Algeria.
Department of Applied Microbiology and Food Sciences, Faculty of Nature and Life Sciences, University of Mohammed Seddik BenyahiaJijel, 98 Ouled Aissa-Jijel 1800-Algeria, Algeria.
Iran J Biotechnol. 2017 Aug 19;15(2):135-142. doi: 10.15171/ijb.1530. eCollection 2017.
The presence of pharmaceuticals at low concentrations (ng to μg) in the environment has become a hot spot for researchers in the past decades due to the unknown environmental impact and the possible damages they might have to the plantae and fauna present in the aquatic systems, as well as to the other living organisms. The aim of the present investigation was to develop a bacterial consortium isolated from different origins to evaluate the ability of such a consortium to remove a mixture of pharmaceuticals in the batch system at lab scale, as well as assessment of its resistance to the other micropollutants present in the environment. Using a closed bottle test, biodegradation of the mixed pharmaceuticals including Diclofenac (DCF), Ibuprofen (IBU), and Sulfamethoxazole (SMX) (at a concentration of 3 mg.L of each drug) by the bacterial consortium was investigated. The test was carried out under metabolic (pharmaceutical was used as the sole source of carbon) and co-metabolic condition (in the presence of glucose). Finally, the ability of the bacterial consortium to resist other micropollutants like antibiotics and heavy metals was investigated. Under the metabolic condition, the mixed bacteria (i.e., consortium) were able to metabolize 23.08% and 9.12% of IBU, and DCF at a concentration of 3 mg.L of each drug, respectively. Whereas, in co-metabolic conditions, IBU was eliminated totally, in addition, 56% of the total concentration of DCF was removed, as well. In both metabolic and cometabolic conditions, removal of SMX was not observed. The selected bacteria were able to resist to most of the applied antibiotics and the used heavy metals, except mercury, where only one strain (S4) was resistant to the later heavy metal. Results suggest that the developed consortium might be an excellent candidate for the application in the bioremediation process for treating ecosystems contaminated with the pharmaceutical.
在过去几十年中,环境中低浓度(纳克至微克)药物的存在已成为研究人员关注的热点,这是由于其对环境的未知影响以及可能对水生系统中的动植物以及其他生物造成的损害。本研究的目的是开发一种从不同来源分离的细菌联合体,以评估该联合体在实验室规模的分批系统中去除药物混合物的能力,以及评估其对环境中其他微污染物的抗性。使用封闭瓶试验,研究了细菌联合体对包括双氯芬酸(DCF)、布洛芬(IBU)和磺胺甲恶唑(SMX)(每种药物浓度为3 mg.L)的混合药物的生物降解。试验在代谢(药物用作唯一碳源)和共代谢条件(存在葡萄糖)下进行。最后,研究了细菌联合体抵抗其他微污染物(如抗生素和重金属)的能力。在代谢条件下,混合细菌(即联合体)能够分别代谢浓度为3 mg.L的IBU和DCF的23.08%和9.12%。而在共代谢条件下,IBU被完全去除,此外,DCF总浓度的56%也被去除。在代谢和共代谢条件下,均未观察到SMX的去除。除汞外,所选细菌能够抵抗大多数应用的抗生素和所用的重金属,只有一个菌株(S4)对后一种重金属具有抗性。结果表明,所开发的联合体可能是用于生物修复受药物污染生态系统的极佳候选者。